These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 9026477

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells.
    Larsson H, Håkanson R, Mattsson H, Ryberg B, Sundler F, Carlsson E.
    Toxicol Pathol; 1988; 16(2):267-72. PubMed ID: 3187355
    [Abstract] [Full Text] [Related]

  • 4. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
    Sanduleanu S, Stridsberg M, Jonkers D, Hameeteman W, Biemond I, Lundqvist G, Lamers C, Stockbrügger RW.
    Aliment Pharmacol Ther; 1999 Feb; 13(2):145-53. PubMed ID: 10102943
    [Abstract] [Full Text] [Related]

  • 5. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.
    Fossmark R, Johnsen G, Johanessen E, Waldum HL.
    Aliment Pharmacol Ther; 2005 Jan 15; 21(2):149-54. PubMed ID: 15679764
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A review of the effects of long-term acid inhibition in animals.
    Carlsson E.
    Scand J Gastroenterol Suppl; 1989 Jan 15; 166():19-23. PubMed ID: 2574909
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Review article: the use of gastric acid-inhibitory drugs--physiological and pathophysiological considerations.
    Waldum HL, Brenna E, Kleveland PM, Sandvik AK, Syversen U.
    Aliment Pharmacol Ther; 1993 Dec 15; 7(6):589-96. PubMed ID: 7909240
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally effective in causing hyperplasia of enterochromaffin-like cells in rat stomach.
    Ryberg B, Bishop AE, Bloom SR, Carlsson E, Håkanson R, Larsson H, Mattsson H, Polak JM, Sundler F.
    Regul Pept; 1989 May 15; 25(2):235-46. PubMed ID: 2756157
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Gastrin/CCK-B receptor antagonists for a novel antiulcer agent].
    Miyata K, Nishida A, Honda K.
    Nihon Yakurigaku Zasshi; 1995 Sep 15; 106(3):171-80. PubMed ID: 8529962
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole.
    Betton GR, Dormer CS, Wells T, Pert P, Price CA, Buckley P.
    Toxicol Pathol; 1988 Sep 15; 16(2):288-98. PubMed ID: 2903544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.